The phase II C-144-01 study (104) used lifileucel (LN-144) for the treatment of 66 patients with stage IIIC/IV unresectable melanoma and showed that after 18.7 months of follow-up, the mDOR was not achieved; an ORR of 36% (2 CR and 22 PR), a disease control rate (DCR) of 80%, and a superior effect in the primary refractory subset of anti-PD-1 or PD-L1 therapy were observed. The gene discussed is CD274; the disease is melanoma.